Advice

following an abbreviated submission

ondansetron orodispersible films (Setofilm®) are accepted for restricted use within NHS Scotland.

Indication under review:
In adults:

  • Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy.
  • Prophylaxis and treatment of delayed nausea and vomiting induced by moderately to highly emetogenic chemotherapy.
  • Prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy.
  • Prophylaxis and treatment of post-operative nausea and vomiting (PONV).

In paediatric populations:

  • Management of chemotherapy-induced nausea and vomiting in children aged  ≥6 months.
  • Prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged  ≥4 years.

SMC restriction: ondansetron orodispersible films are restricted to use in patients with an enhanced risk of aspiration or who experience difficulties in swallowing.

Generic preparations of ondansetron are available at a lower cost than the proprietary products.

Download detailed advice90KB (PDF)

Download

Medicine details

Medicine name:
ondansetron (Setofilm)
SMC ID:
912/13
Indication:
In adults: Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy. Prophylaxis and treatment of delayed nausea and vomiting induced by moderately to highly emetogenic chemotherapy. Prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting (PONV). In paediatric populations: Management of chemotherapy-induced nausea and vomiting in children aged ≥6 months. Prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years.
Pharmaceutical company
Norgine Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published
11 November 2013